Host defense against oropharyngeal and vaginal candidiasis: Site- specific differences

Revista Iberoamericana de Micologia

Volumn 16, Issue 1, 1999, Pages 8-15

  Fidel Jr , Paul L ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Candida albicans; Host defense mechanisms; Immunosuppression; Mucosal candidiasis; Oral candidiasis; Vaginal candidiasis

Indexed keywords

ANTIBIOTIC AGENT; CONTRACEPTIVE AGENT; STEROID;

CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; OPPORTUNISTIC INFECTION; OROPHARYNX; PERIPHERAL CIRCULATION; REVIEW; RISK FACTOR; VAGINITIS;

EID: 6544293463     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311:354-357.
2. Macher AM. The pathology of AIDS. Public Health Report 1988;103:246-50.
3. Clift RA. Candidiasis in the transplant patient Amer J Med 1984;77 (Suppl. 4D):34-38
4. Knight L, Fletcher J. Growth of Candida albicans in saliva: Stimulation by glucose associated with antibiotics, corticosteriods and diabetes mellitus. J Infect Dis 1971; 123:371-377.
5. Odds FC. Chronic mucocutaneous candidiosis. In: Candida and candidosis. Baltimore, University Park Press. 1988: 104-110.
6. Hauman CH, Thompson IO, Theunissen F, Wolfaart P. Oral Carriage of Candida in healthy and HIV-seropositive persons. Oral Surg Oral Med Oral Pathol 1993;76:570-572.
7. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci 1988;544:547-557.
8. Cenci E, Romani L, Vecchiarelli A, Puccetti P, Bistoni F T cell subsets and INF-gamma production in resistance to systemic candidosis in immunized mice. J Immunol 1990;144:4333-4339.
9. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992,14 (Suppl. 1):S148-S153
10. Cenci E, Mencacci A, Spaccapelo R, Tonnetti L, et al. T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 1995;171:1279-1288.
11. Romani L, Puccetti P, Bistoni F, Romagnani S. Biological role of Th cell subsets in candidiasis. In: Th1 and Th2 cells in health and disease. Farmington, Karger, 1996: 114-137.
12. Kirkpatrick CH. Chronic mucocutaneous candidiasis. Eur J Clin Microbiol Infect Dis 1989;8:448-456
13. Liljemark WF, Gibbons RJ Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect Immun 1973;8:846-849.
14. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-4218.
15. Fidel PL Jr., Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis Infect Immun 1993;61:1990-1995.
16. Fidel PL Jr., Lynch ME, Sobel JD. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun 1993;61 4202-4207.
17. Fidel PL Jr , Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis Infect Immun 1994;62:1032-1038.
18. Fidel PL Jr, Lynch ME, Conaway DH, Tait L, Sobel JD. Mice immunized by primary vaginal C. albicans infection develop acquired vaginal mucosal immunity Infect Immun 1995;63:547-553.
19. Fidel PL Jr., Lynch ME, Sobel JD. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun 1995;63:2403-2408
20. Hector RF, Domer JE, Carrow EW. Immune responses to Candida albicans in genetically distinct mice. Infect Immun 1982;38:1020-1028.
21. Fidel PL Jr, Cutright JL, Sobel JD. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect Immun 1995;63:4191-194.
22. Kirkpatrick CH, Rich RR, Bennett JE. Chronic mucocutaneous candidiasis Model building in cellular immunity. Ann Intern Med 1971;75:955-978
23. Mathur S, Virella G, Koistinen J, Horger EO, Mahvi TA, Fudenberg HH. Humoral immunity in vaginal candidiasis. Infect Immun 1977;15:287-294.
24. Witkin SS. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans. Obstet Gynecol 1986;66:696-699.
25. Witkin SS, Hirsch J, Ledger WJ. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol 1986;155:790-795.
26. Hobbs JR, Briden D, Davidson F, Kahan M, Oates JK. Immunological aspects of Candidal vaginitis. Proc R Soc Med 1977;70:11-14.
27. Fong IW, McCleary P, Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol 1992;166:887-890.
28. Corrigan EM, Clancy RL, Dunkley ML, Eyers FM, Beagley KW Cellular immunity in recurrent vulvovaginal candidiasis. Clin Exp Immunol 1998;111:574-578.
29. Syverson RA, Buckley H, Gibian J, Ryan JJM. Cellular and humoral immune status in women with chronic Candida vaginitis. Am J Obstet Gynecol 1979;134:624-627.
30. Mendling W, Koldovsky U. Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses. Infect Dis Obstet Gynecol 1996;4 225-231.
31. Fidel PL Jr, Lynch ME, Redondo-Lopez V, Sobel JD, Robinson R. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J Infect Dis 1993;168:1458-1465.
32. Burns DN, Tuomala R, Chang BH, et al. Vaginal colonization or infection with Candida albicans in human immunodeficiency virus-infected women during pregnancy and during postpartum period. Clin Infect Dis 1997;24:201-210.
33. Duerr A, Sierra MF, Feldman J, Clarke LM. Ehlich I, Dehovitz J. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol 1997;90:252-256.
34. Spinillo A, Michelone G, Cavanna C, Colonna L, Capuzzo E, Nicola S. Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women. Genitourin Med 1994;70:268-272.
35. White MH. Is vutvovaginal candidiasis an AIDS-related illness. Clin Infect Dis 1996;22(Suppl 2):S124-S127
36. Fidel PL Jr., WoIf NA, Cutright JL, et al. Candida-specific Th1/Th2 reactivity in HIV+ women. ASM Conference on Candida and Candidiasis. Washington DC, 1996.
37. Clark RA, Blakley SA, Rice J, Brandon W. Predictors of HIV progression in women. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:43-50.
38. Schuman P, Sobel JD, Ohmit S, et al. Mucosal Candida colonization and candidiasis in women with or at risk for Human immunodeficiency virus infection. Clin Infect Dis 1998;27:1161-1167.
39. Rhoads JL, Wright DC, Redfield RR, Burke DS Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 1987;257:3105-3107
40. Imam N, Carpenter CCJ, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal Candida infections in HIV- seropositive women Am J Med 1990;89:142-146.
41. Parr MB, Parr EL. Antigen recognition in the female reproductive tract. I Uptake of intraluminal protein tracers in the mouse vagina J Reprod Immunol 1990;17 101-14
42. Parr MB, Kepple L, Parr EL Antigen recognition in the female reproductive tract II. Endocytosis of horseradish peroxidase by Langerhans cells in murine vaginal epithelium. Biol Reprod 1991;45:261-5.
43. Itohara S, Farr AG, Lafaille JJ, et al. Homing of a gamma/delta thymocyte subset with homogenous T-cell receptors to mucosal epithelia. Nature 1990;343:754-7.
44. Nandi D, Allison JP. Phenotypic analysis and gamma/delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol 1991;147:1773-8.
45. Fidel PL Jr., Wolf NA, KuKuruga MA. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 1996;64:3793-9.
46. Rakasz E, Hagen M, Sandor M, Lynch RG. γδ T cells of the murine vagina: T cell response in vivo in the absence of the expression of CD2 and CD28 molecules. Int immunol 1997;9(1):161-7.
47. + vaginal T cells. 1998; Submitted.
48. Janeway CA, Haque S, Smith LA, Saizawa K. The role of the murine L3T4 molecule in T cell activation: differential effects of anti-L3T4 on activation by monoclonal anti-receptor antibodies. J Mol Cell Immunol 1987;3:121-31.
49. Fidel PL Jr., Luo W, Chabain J, Wolf NA, Van Buren E. Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. Infect Immun 1997;65:3939-43.
50. White HD, Crassi KM, Givan AL, et al. CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause. J Immunol 1997;158:3017-27
51. Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages, and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992;67:628-34
52. Lohman B, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 1995;155:5855-60.
53. Cantorna MT, Mook D, Balish E. Resistance of congenitally immunodeficient gnotobiotic mice to vaginal candidasis. Infect Immun 1990;58 3813-5.
54. Jones-Carson J, Vazquez-Torres A, van der Heyde, Warner T, Wagner RD, Balish E. γδ T cell-induced nitric oxide production enhances resistance to mucosal candidiasis Nature Med. 1995;6:552-7.
55. Fidel PL Jr, Luo W, Steele C, et al. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999; in press.
56. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance Infect Immun 1991;59 4647-54.
57. Romani L, Mencacci A, Cenci E, et al. CD+ subset expression in murine candidiasis J Immunol 1993;150:925-31.
58. Fidel PL Jr., Ginsburg KA, Cutright JL, et al. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: Evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997;176 728-39.
59. Rogers TJ, Balish E. Immunity to Candida albicans Microbiol Rev 1980;44:660-82.
60. Polonelli L, De Bernardis F, Conti S, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory,yeast killer toxin-like anti-idiotypic antibodies. J Immunol 1994;152:3175-82.
61. Polonelli L, De Bernardis F, Conti S, et al. Human natural yeast killer toxin-like candidicidal antibodies. J Immunol 1996;156:1880-5.
62. Cassone A, Boccanera M, Adriani DA, Santoni G, De Bemardis F. Rats clearing a vaginal infection by Candida albicans aquire specific, antibody-mediated resistance to vaginal infection. Infect Immun 1995;63:2619-2624.
63. De Bernardis F, Boccanera M, Adrians D, Spreghini E, Santoni G, Cassone A. Protective role of antimannan and antiaspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997;65:3399-3405.
64. Black CA, Eyers FM, Russell A, Dunkley ML, Clancy RL, Beagley KW. Acute neutropenia in inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 1998;66:1273-1275.
65. Djeu JY, Blanchard DK. Regulation of human polymorphonuclear neutrophil (PMN) activity against Candida albicans by large granular lymphocytes via release of a PMN-activating factor. J Immunol 1987;139:2761-2767.
66. Arancia G, Molinari A, Crateri P, et al. Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans. Infect Immun 1995;63:280-288.
67. Parr MB, Parr EL. Langerhans cells and T lymphocyte subsets in the murine vagina and cervix. Biol Reprod 1991;44:491-8.
68. Hedges SR, Agace WW, Svanborg C. Epithelial cytokine responses and mucosal cytokine networks. Trends Microbiol 1995; 3:266-270.
69. Fratti RA, Ghannoum MA, Edwards JE Jr., Filler SG. Gamma interferon protects endothelial cells from damage by Candida albicans by inhibiting endothelial cell phagocytosis. Infect Immun 1996;64:4714-18.
70. Steele C, Ozenci H, Luo W, Scott M, Fidel PL Jr. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 1999; in press.
71. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992;73:171-180.
72. Leigh JE, Steele C, Wormley FL Jr, et al. Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: A pilot study in HIV-positive individuals with oropharyngeal candidiasis J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:373-380.
73. Meitner SW, Bowen WH, Haidaris CG. Oral and esophageal Candida albicans infection in hyposalivatory rats. Infect Immun 1990;58:2228-3226.
74. Allen CM, Saffer A, Meister RK, Beck FM, Bradway S. Comparison of a Iesion-inducing isolate and a non-lesional isolate of Candida albicans in an immunosuppressed rat model of oral candidiasis. J Oral Pathol Med 1994;23:133-139.
75. Chakir J, Cote L, Coulombe C, Deslauriers N. Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice. Oral Microbiol Immunol 1994;9:88-94.
76. Deslauriers N, Cote L, Montplaisir S, De Repentigny L. Oral carriage of Candida albicans in murine AIDS. Infect Immun 1997;65:661-667
77. Odden K, Schenck K, Hurlen B. High numbers of T cells in gingiva from patients with human immunodeficiency virus (HIV) infection. J Oral Pathol Med 1995;24:413-419.
78. Steidley KE, Thompson SH, McQuade MJ, Strong SL, Scheidt MJ, Van Dyle TE. A comparison of T4:T8 lymphocyte ratio in the periodontal lesion of healthy and HIV-positive patients. J Periodontol 1992;63:753-756.
79. Coogan MM, Sweet SP, Challacombe SJ. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun 1994;62:892-896.
80. Pollock JJ, Santarpia RP, Heller HM, et al. Determination of salivary anticandidal activities in healthy adults and patients with AIDS: a pilot study. J Acquir Immune Defic Syndr 1992;5:610-618.